Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03536936
Other study ID # Migraine Brain Perfusion
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date April 30, 2018

Study information

Verified date May 2018
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to retrospectively evaluate brain perfusion and oxygenation in acute migraine attacks. Magnetic resonance perfusion and susceptibility weighted imaging are the technics to measure perfusion and oxygenation respectively.


Description:

The aim of the study is to demonstrate a possible correlation between areas of hypoperfusion and prominent cortical veins during migraine attacks.

These focal ares of altered vascular supply of the brain will be evaluated for correlation with topograhy of symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date April 30, 2018
Est. primary completion date April 30, 2018
Accepts healthy volunteers
Gender All
Age group 6 Years to 80 Years
Eligibility Inclusion Criteria:

final clinical diagnosis of migraine

Exclusion Criteria:

brain tumors, seizures/epilepsy, confirmed cerebral infarct from cerebral atery occlusion, sinus vein thrombosis;

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne

References & Publications (9)

Bosemani T, Burton VJ, Felling RJ, Leigh R, Oakley C, Poretti A, Huisman TA. Pediatric hemiplegic migraine: role of multiple MRI techniques in evaluation of reversible hypoperfusion. Cephalalgia. 2014 Apr;34(4):311-5. doi: 10.1177/0333102413509432. Epub 2 — View Citation

Charles A, Brennan KC. The neurobiology of migraine. Handb Clin Neurol. 2010;97:99-108. doi: 10.1016/S0072-9752(10)97007-3. — View Citation

Fedak EM, Zumberge NA, Heyer GL. The diagnostic role for susceptibility-weighted MRI during sporadic hemiplegic migraine. Cephalalgia. 2013 Nov;33(15):1258-63. doi: 10.1177/0333102413491027. Epub 2013 Jun 13. — View Citation

Floery D, Vosko MR, Fellner FA, Fellner C, Ginthoer C, Gruber F, Ransmayr G, Doerfler A, Uder M, Bradley WG. Acute-onset migrainous aura mimicking acute stroke: MR perfusion imaging features. AJNR Am J Neuroradiol. 2012 Sep;33(8):1546-52. doi: 10.3174/ajn — View Citation

Förster A, Wenz H, Kerl HU, Brockmann MA, Groden C. Perfusion patterns in migraine with aura. Cephalalgia. 2014 Oct;34(11):870-6. doi: 10.1177/0333102414523339. Epub 2014 Feb 19. — View Citation

Kao HW, Tsai FY, Hasso AN. Predicting stroke evolution: comparison of susceptibility-weighted MR imaging with MR perfusion. Eur Radiol. 2012 Jul;22(7):1397-403. doi: 10.1007/s00330-012-2387-4. Epub 2012 Feb 10. — View Citation

Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology. 1999 Aug 11;53(3):537-42. — View Citation

Mourand I, Menjot de Champfleur N, Carra-Dallière C, Le Bars E, Roubertie A, Bonafé A, Thouvenot E. Perfusion-weighted MR imaging in persistent hemiplegic migraine. Neuroradiology. 2012 Mar;54(3):255-60. doi: 10.1007/s00234-011-0946-z. Epub 2011 Aug 11. — View Citation

Planche V, Chassin O, Leduc L, Regnier W, Kelly A, Colamarino R. Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy. Cephalalgia. 2014 Jan;34(1):73-7. doi: 10.1177/0333102413505237. Epub 2013 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Focal cerebral hypoperfusion and elevated oxygenation in acute migraine attack Focal cerebral hypoperfusion and elevated oxygenation in acute migraine attack, measured with visual scores on imaging, using a consensus between two readers Patients, who are admitted to hospital, undergo magnetic resonance imaging within 5 days of migraine attack; time frame: symptoms to imaging : 5 days;
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A